Frontiers in Neurology | Multiple Sclerosis and Neuroimmunology

Original Research

Published on 11 Jul 2025

Neuropsychiatric disorders among Ecuadorian patients with multiple sclerosis and neuromyelitis optica spectrum disorder

in Multiple Sclerosis and Neuroimmunology

Edgar Patricio Correa-Díaz
Ruth Jimbo Sotomayor
Jorge Rubén Pilco Romero
Patricio Alexander Merino Aguilera

Frontiers in Neurology

doi 10.3389/fneur.2025.1587804

160 views

Original Research

Published on 10 Jul 2025

Emerging epidemiological trends of multiple sclerosis among adults aged 20–54 years, 1990–2021, with projections to 2035: a systematic analysis for the global burden of disease study 2021

in Multiple Sclerosis and Neuroimmunology

Ling-yun Wang
Wen-fu Wang
Shu-yin Hui
Li Yang
Yue-xian Liu
Hang-juan Li

Frontiers in Neurology

doi 10.3389/fneur.2025.1616245

303 views

Original Research

Accepted on 07 Jul 2025

Serum Homocysteine Levels Predict Poor Recovery and Relapse in First-Attack Myelin Oligodendrocyte Glycoprotein Antibody Disease

in Multiple Sclerosis and Neuroimmunology

Yanfei Li
Yanjie Jia

Frontiers in Neurology

doi 10.3389/fneur.2025.1619479

480 views

Original Research

Published on 07 Jul 2025

Fatigue and its correlation with anxiety and depression in patients with multiple sclerosis in China

in Multiple Sclerosis and Neuroimmunology

Han Wang
Rongrong Wang
Runze Zhao
Gaopan Zhang
Guoxun Zhang
Xiongfei Zhao

Frontiers in Neurology

doi 10.3389/fneur.2025.1604540

407 views

Original Research

Accepted on 04 Jul 2025

Characteristics and Correlations of Sleep Disorders in Patients with Relapsing-Remitting Multiple Sclerosis in China: A Cross-Sectional Study

in Multiple Sclerosis and Neuroimmunology

Rongrong Wang
Teng'teng Zhang
Han Wang
Yao Ren
Runze Zhao
Gaopan Zhang
Guoxun Zhang
Xiongfei Zhao

Frontiers in Neurology

doi 10.3389/fneur.2025.1608802

137 views

Original Research

Published on 04 Jul 2025

FCRL3 genetic variants drive autoimmune pathogenesis in multiple sclerosis and neuromyelitis optica spectrum disorders

in Multiple Sclerosis and Neuroimmunology

Hui-Fen Huang
Qi-Bing Liu
Yong-Feng Xu
Gui-Xian Zhao
Hai-Peng Liu
Hao Yu
Zhi-Ying Wu

Frontiers in Neurology

doi 10.3389/fneur.2025.1552149

566 views

Original Research

Published on 03 Jul 2025

Cladribine tablets as therapy for advanced relapsing-remitting multiple sclerosis: a 4-year follow-up real-world, multi-center, retrospective, cohort study

in Multiple Sclerosis and Neuroimmunology

Aleksandra Pogoda-Wesołowska
Adam Stępień
Marcin Wnuk
Monika Marona
Elżbieta Tokarz-Kupczyk
Karolina Piasecka-Stryczyńska
Konrad Rejdak
Anna Jamroz-Wiśniewska
Monika Adamczyk-Sowa
Katarzyna Kubicka-Bączyk

Frontiers in Neurology

doi 10.3389/fneur.2025.1626317

591 views

Review

Accepted on 02 Jul 2025

Current understanding of neuroimmune dynamics throughout the lifespan

in Multiple Sclerosis and Neuroimmunology

Xin Yi Yeo
Yunseon Choi
Yeonhee Hong
Hyuk Nam Kwon
Sangyong Jung

Frontiers in Neurology

doi 10.3389/fneur.2025.1611124

117 views

Original Research

Accepted on 30 Jun 2025

Mental health outcomes in pregnant women with relapsing-remitting multiple sclerosis: A longitudinal cohort study

in Multiple Sclerosis and Neuroimmunology

Lena Kristina Pfeffer
Caren Ramien
Anja Harrison
Kostas Patas
Kristina Grentzenberg
Stefanie Reinhardt
Andrea Mönch
Max Kaufmann
Stefan Gold
Christoph Heesen

Frontiers in Neurology

doi 10.3389/fneur.2025.1619021

140 views

Review

Accepted on 23 Jun 2025

Eukaryotic initiation factors: central factor associating mRNA translational plasticity during neuropathic pain progression

in Multiple Sclerosis and Neuroimmunology

Xinshuo Li
Haibo Zhan
Xindan Zhang
Jiayi Li
Xiangrui Li
Xihua Lu
Changhong Miao
Chunli Zhou
Zhen Zhang

Frontiers in Neurology

doi 10.3389/fneur.2025.1566205

171 views

Original Research

Published on 16 Jun 2025

Impact of visual discomfort symptoms on SDMT performance among persons with MS

in Multiple Sclerosis and Neuroimmunology

Michelle H. Chen
Timothy J. Rich
Nancy Chiaravalloti
Yael Goverover
Silvana L. Costa

Frontiers in Neurology

doi 10.3389/fneur.2025.1569451

721 views

Original Research

Accepted on 02 Jun 2025

Autoantibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with psychotic symptoms

in Multiple Sclerosis and Neuroimmunology

Nikita A. van de Burgt
Laila Kulsvehagen
Marina Mané Damas
Luc Lutz
Anne-Catherine Lecourt
Clara Montserrat
Anita Vinke
Cem I Küçükali
Shenghua Zong
Carolin Correia-Hoffmann

Frontiers in Neurology

doi 10.3389/fneur.2025.1593042

296 views

Systematic Review

Published on 30 May 2025

A narrative review of the economic burden of myelin oligodendrocyte glycoprotein antibody-associated disease and analogous conditions

in Multiple Sclerosis and Neuroimmunology

Leonard Lee
Joshua Byrnes
Cathryn Hope
Hansoo Kim

Frontiers in Neurology

doi 10.3389/fneur.2025.1506465

1,332 views

Original Research

Published on 29 May 2025

Progression independent of relapsing biology in multiple sclerosis: a real-word study

in Multiple Sclerosis and Neuroimmunology

Heather Y. F. Yong
Carlos Camara-Lemarroy

Frontiers in Neurology

doi 10.3389/fneur.2025.1595929

1,063 views

Original Research

Published on 21 May 2025

CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany

in Multiple Sclerosis and Neuroimmunology

Mathias Buttmann
Martin S. Weber
Sven G. Meuth
Sandra Blümich
Stefanie Hieke-Schulz
Petra Dirks
Julius C. Eggebrecht
Tjalf Ziemssen

Frontiers in Neurology

doi 10.3389/fneur.2025.1564327

1,944 views

Original Research

Published on 21 May 2025

Long-term outcomes in leucine-rich glioma inactivated-1 autoimmune encephalitis and associated biomarkers of inflammation and neuronal and glial injury

in Multiple Sclerosis and Neuroimmunology

Tyler L. Borko
Phillip Winters
Kelli M. Money
Stefan Sillau
Sadie Eggmann
Sean Selva
Alanna Ritchie
Ryan Kammeyer
Gregory P. Owens
Jeffrey L. Bennett

Frontiers in Neurology

doi 10.3389/fneur.2025.1583892

1,451 views

Neuropsychiatric disorders among Ecuadorian patients with multiple sclerosis and neuromyelitis optica spectrum disorder

Emerging epidemiological trends of multiple sclerosis among adults aged 20–54 years, 1990–2021, with projections to 2035: a systematic analysis for the global burden of disease study 2021

Serum Homocysteine Levels Predict Poor Recovery and Relapse in First-Attack Myelin Oligodendrocyte Glycoprotein Antibody Disease

Fatigue and its correlation with anxiety and depression in patients with multiple sclerosis in China

Characteristics and Correlations of Sleep Disorders in Patients with Relapsing-Remitting Multiple Sclerosis in China: A Cross-Sectional Study

FCRL3 genetic variants drive autoimmune pathogenesis in multiple sclerosis and neuromyelitis optica spectrum disorders

Cladribine tablets as therapy for advanced relapsing-remitting multiple sclerosis: a 4-year follow-up real-world, multi-center, retrospective, cohort study

Current understanding of neuroimmune dynamics throughout the lifespan

Mental health outcomes in pregnant women with relapsing-remitting multiple sclerosis: A longitudinal cohort study

Eukaryotic initiation factors: central factor associating mRNA translational plasticity during neuropathic pain progression

Impact of visual discomfort symptoms on SDMT performance among persons with MS

Autoantibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with psychotic symptoms

A narrative review of the economic burden of myelin oligodendrocyte glycoprotein antibody-associated disease and analogous conditions

Progression independent of relapsing biology in multiple sclerosis: a real-word study

CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany

Long-term outcomes in leucine-rich glioma inactivated-1 autoimmune encephalitis and associated biomarkers of inflammation and neuronal and glial injury

Emerging epidemiological trends of multiple sclerosis among adults aged 20–54 years, 1990–2021, with projections to 2035: a systematic analysis for the global burden of disease study 2021